Anemia and hemoglobinopathies

PubMed Free Full Text

Hemolytic anemia

Asia-Pacific

• Nephrology
  • Management of Atypical Haemolytic Uraemic Syndrome With Triggers: Diagnostic and Treatment Algorithms From an Asia-Pacific Perspective [2025]

Australia

• National Blood Authority
  • Autoimmune haemolytic anaemia (AIHA)

Australia, Europe

• Clinical Epidemiology
  • Epidemiology of Atypical Hemolytic Uremic Syndrome: A Systematic Literature Review [2020]

Brazil

• Brazilian Journal of Nephrology
  • Recommendations for diagnosis and treatment of Atypical Hemolytic Uremic Syndrome (aHUS): an expert consensus statement from the Rare Diseases Committee of the Brazilian Society of Nephrology (COMDORA-SBN) [2025]

Canada

• Government of Alberta
  • Alberta public health disease management guidelines : haemolytic uremic syndrome

China

• BMC Nephrology
  • Incidence and cost of haemolytic uraemic syndrome in urban China: a national population-based analysis [2022]

Egypt

• Egyptian Pediatric Association Gazette
  • Diagnosis, management and prevention of Pediatric Acute Hemolytic Anemia: Egyptian adapted evidence-based clinical practice guidelines [2023]

Europe

• European Hematology Association
  • Recommendations regarding splenectomy in hereditary hemolytic anemias [2017]

France

• Blood Advances
  • Drug-induced immune hemolytic anemia: detection of new signals and risk assessment in a nationwide cohort study [2024]

• EuroSurveillance
  • Paediatric haemolytic uraemic syndrome related to Shiga toxin-producing Escherichia coli, an overview of 10 years of surveillance in France, 2007 to 2016 [2019]

• PLoS ONE
  • Epidemiology and care management of Paroxysmal Nocturnal Hemoglobinuria (PNH) in a real-world setting in France: Description from the French National Hospitalization Database [2026]

High-income countries

• Drugs
  • Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition [2025]

India

• Indian Academy of Pediatrics
  • Hemolytic uremic syndrome in a developing country: Consensus guidelines [2019]

• Lancet Regional Health - Southeast Asia
  • Management of autoimmune haemolytic anaemia in low-to-middle income countries: current challenges and the way forward [2023]

International

• American Journal of Hematology
  • Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency [2019]

• Blood Advances
  • Efficacy of eculizumab discontinuation in atypical hemolytic uremic syndrome: a systematic review and meta-analysis [2025]

• Bulletin of the World Health Organization
  • New WHO classification of genetic variants causing G6PD deficiency [2024]

• Clinical Pharmacology & Therapeutics
  • Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype [2023]

• Lancet Haematology
  • Diagnosis and management of pyruvate kinase deficiency: international expert guidelines [2024]

• Minerva Medica
  • Treatment of autoimmune hemolytic anemia: novel and investigational approaches [2025]

Iran

• Iranian Journal of Kidney Diseases
  • The Prevalence and Incidence of Hemolytic Uremic Syndrome in Iran, a Systematic Review and Meta-analysis [2020]

Italy

• Blood Transfusion
  • Second-line therapy in paediatric warm autoimmune haemolytic anaemia. Guidelines from the Associazione Italiana Onco-Ematologia Pediatrica (AIEOP) [2018]
  • Diagnosis and management of newly diagnosed childhood autoimmune haemolytic anaemia. Recommendations from the Red Cell Study Group of the Paediatric Haemato-Oncology Italian Association [2017]

• Pharmacological Research
  • Multidisciplinary consensus on the diagnosis and management of patients with atypical Hemolytic Uremic Syndrome (complement-mediated TMA): Recommendations from Italian scientific societies, patient associations and regulators [2025]

Japan

• Scientific Reports
  • Annual trends in atypical haemolytic uremic syndrome management in Japan and factors influencing early diagnosis and treatment: a retrospective study [2024]

Middle East

• Clinical and Experimental Medicine
  • Clinical characteristics and management of paroxysmal nocturnal hemoglobinuria in the Middle East: a narrative review [2025]

Norway

• BMC Infectious Diseases
  • Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999–2008 [2016]

Republic of Korea

• Blood Research
  • Korean clinical practice guidelines for the diagnosis of hereditary hemolytic anemia [2022]

• Journal of Korean Medical Science
  • Epidemiological Study of Hereditary Hemolytic Anemia in the Korean Pediatric Population during 1997–2016: a Nationwide Retrospective Cohort Study [2020]
  • Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea [2016]

• Korean Journal of Internal Medicine
  • Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome [2020]

Saudi Arabia

• Annals of Thoracic Medicine
  • Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension associated with hemolytic anemia [2014]

Singapore

• Annals Academy of Medicine Singapore
  • Consensus recommendations for optimising the diagnosis and treatment of paroxysmal nocturnal haemoglobinuria in Singapore [2025]

Spain

• Nefrología
  • An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document [2015]

Taiwan

• Journal of the Formosan Medical Association
  • Atypical hemolytic uremic syndrome: Consensus of diagnosis and treatment in Taiwan [2023]

Türkiye

• Turkish Journal of Pediatrics
  • Management of pediatric hemolytic uremic syndrome [2024]

United Kingdom

• British Society for Haematology
  • The diagnosis and management of primary autoimmune haemolytic anaemia [2017]
  • Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia [2017]
  • Guidelines for the diagnosis and management of hereditary spherocytosis – 2011 update [2011]

• National Institute for Health and Care Excellence
  • Iptacopan for treating paroxysmal nocturnal haemoglobinuria [2024]
  • Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria [2024]
  • Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over [2024]
  • Ravulizumab for treating atypical haemolytic uraemic syndrome [2021]
  • Autoimmune haemolytic anaemia: rituximab [2015]

• PharmacoEconomics
  • Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria [2025]

United States

• American Family Physician
  • Hemolytic Anemia: Evaluation and Differential Diagnosis [2018]

• Journal of Comparative Effectiveness Research
  • The cost-effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA [2023]

• National Kidney Foundation
  • An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group [2024]

• Pharmaceutics
  • Development of New Drugs for Autoimmune Hemolytic Anemia [2022]

• PLoS ONE
  • Prevalence and incidence of primary autoimmune hemolytic anemia and cold agglutinin disease in the United States, 2016-2023 [2025]

WHO

• World Health Organization
  • WHO information note on delayed haemolytic anaemia following treatment with artesunate [2013]

{Related topics}

• Topic
  • Anemia